Evolent Health
EVH
203 hedge funds and large institutions have $3.34B invested in Evolent Health in 2023 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 84 increasing their positions, 73 reducing their positions, and 30 closing their positions.
15% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 73
3.45% more ownership
Funds ownership: 104.46% → 107.91% (+3.5%)
6% less capital invested
Capital invested by funds: $3.55B → $3.34B (-$211M)
6% less funds holding
Funds holding: 217 → 203 (-14)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
40% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 30
71% less call options, than puts
Call options by funds: $1.69M | Put options by funds: $5.9M
Top Buyers
Top Sellers
| 1 |
Invesco
Atlanta,
Georgia
|
-$30.2M |
| 2 |
RI
Redwood Investments
Boston,
Massachusetts
|
-$12.8M |
| 3 |
Allspring Global Investments
Charlotte,
North Carolina
|
-$11.5M |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$10.2M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$9.53M |
EVH Hedge Fund Activity: Q3 2023 in Review
203 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Evolent Health (EVH) for Q3 2023, worth a combined $3.34B — down 5.9% from $3.55B a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of EVH and 18 opened new positions — a net loss of 12 holders — while 73 trimmed existing stakes and 84 added.
The largest buyer was RA Capital Management, opening a new position worth an estimated $76.1M. The largest seller was Invesco, cutting an estimated $30.2M.
- 203 institutional investors held Evolent Health (EVH) as of Q3 2023, down from 217 in Q2 2023.
- Funds reported $3.34B of Evolent Health stock for Q3 2023, down 5.9% quarter-over-quarter.
- 18 funds opened new Evolent Health positions in Q3 2023 and 30 closed out, a net change of -12 holders.
- The largest Evolent Health buyer in Q3 2023 was RA Capital Management, an estimated $76.1M added.
- The largest Evolent Health seller in Q3 2023 was Invesco, an estimated $30.2M sold.
Based on aggregated 13F filings for Q3 2023.